The SNPs in pre-miRNA are related to the response of capecitabine-based therapy in advanced colon cancer patients

• DOI: 10.18632/oncotarget.23190
• Publication Date: 2017-12-13T16:23:40Z
• Authors: Yong Mao; Chengda Zou; Fanyi Meng; Jiehong Kong; Weipeng Wang; Dong Hua
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Research Paper; 3. Good health

// Yong Mao 1, * , Chengda Zou 2, 3, Fanyi Meng 2 Jiehong Kong Weipeng Wang and Dong Hua 1 Department of Medical Oncology, Institute Cancer, Affiliated Hospital Jiangnan University The Fourth People’s Wuxi, Wuxi 214062, China Center for Drug Metabolism Pharmacokinetics, College Pharmaceutical Sciences, Soochow University, Suzhou 215123, 3 Orthopedics, Children’s These authors contributed equally to this work Correspondence to: Wang, email: [e-mail] Hua, [e-mail] Keywords: colon cancer; capecitabine; polymorphism; microRNA Received: September 25, 2017      Accepted: December 01, Published: 11, 2017 ABSTRACT single nucleotide polymorphisms (SNPs) in the precursor (pre-miRNA) may modulate posttranscriptional regulation gene expression explain individual sensitivity chemotherapy. Here we investigated correlation between 23 SNPs pre-miRNA efficacy capecitabine-based chemotherapy 274 advanced cancer patients. Statistical analysis indicated that much more patients with rs744591 A/C(48.03%), C/C (53.45%) or C allele (49.73%) responded than those A/A genotype (33.71%). response rates rs745666 G/C heterozygous (35.25%) carriers (39.69%) were apparently less G/G homozygous (56.25%). Moreover, three rs2114358, rs35770269, rs73239138 significantly associated occurrence side effects rs2114358 (OR = 2.016) rs35770269 T 2.299) prone endure adverse events. However, incidence effect was lower carrying A 0.500). Our findings demonstrate genetic variations influence